{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=22", "query": { "condition": "Advanced Non-small Cell Lung Cancer (NSCLC)", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 1796, "total_pages": 180, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T21:32:04.930Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00487669", "title": "Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-small Cell Lung Cancer" ], "interventions": [ { "name": "paclitaxel poliglumex, pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2006-10", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2014-01-09", "last_synced_at": "2026-10-14T21:32:04.930Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00487669" }, { "nct_id": "NCT07566052", "title": "A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Setidegrasib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 356, "start_date": "2026-04-28", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-14T21:32:04.930Z", "location_count": 7, "location_summary": "Glendale, California • Los Angeles, California • San Francisco, California + 4 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Edison", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07566052" }, { "nct_id": "NCT07223047", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Malignancies", "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "BMS-986523", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2025-11-25", "completion_date": "2028-10-13", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-14T21:32:04.930Z", "location_count": 4, "location_summary": "Baltimore, Maryland • San Antonio, Texas • West Valley City, Utah + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223047" }, { "nct_id": "NCT00036790", "title": "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Colorectal Cancer", "Head and Neck Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Diseases", "Prostate Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-14T21:32:04.930Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036790" }, { "nct_id": "NCT00734890", "title": "Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Lymphoma", "Lymphoproliferative Disorder", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "vandetanib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2008-03", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2012-03-16", "last_synced_at": "2026-10-14T21:32:04.930Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00734890" }, { "nct_id": "NCT07444814", "title": "Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "Ovarian Cancer", "Ovarian Cancer Metastatic", "Ovarian Cancer Metastatic Recurrent", "Non-squamous EGFR Wt NSCLC", "Platinum Resistant Ovarian Cancer", "PROC" ], "interventions": [ { "name": "HWK-007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Whitehawk Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2025-12-19", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-14T21:32:04.930Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07444814" }, { "nct_id": "NCT05394831", "title": "A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "EGFR Mutant Advanced Non-small Cell Lung Cancer" ], "interventions": [ { "name": "JIN-A02", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "J Ints Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2023-07-30", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-14T21:32:04.930Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05394831" }, { "nct_id": "NCT04751747", "title": "Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Locally Advanced Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Contrast Agent", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-02-11", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-14T21:32:04.930Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04751747" }, { "nct_id": "NCT00091663", "title": "A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer", "Non-small-cell Lung Carcinoma" ], "interventions": [ { "name": "Tarceva (erlotinib HCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2004-08", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2014-03-04", "last_synced_at": "2026-10-14T21:32:04.930Z", "location_count": 92, "location_summary": "Huntsville, Alabama • Anchorage, Alaska • Glendale, Arizona + 83 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091663" }, { "nct_id": "NCT06039384", "title": "A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "INCB099280", "type": "DRUG" }, { "name": "adagrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-12-28", "completion_date": "2025-07-11", "has_results": true, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-14T21:32:04.930Z", "location_count": 5, "location_summary": "Los Angeles, California • Greeley, Colorado • Detroit, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Greeley", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06039384" } ] }